- Linaclotide (Constella), for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. Its use should be restricted to patients who have not responded adequately to or cannot tolerate all other suitable treatment options.
Two medicines were rejected:
- Fluocinolone intravitreal implant (Iluvien), for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.
- Ivacaftor (Kalydeco), for the treatment of cystic fibrosis in patients aged 6 years and older who have a G551D mutation in the CFTR gene.
Further information: Scottish Medicines Consortium